Accession Number: | 0001562180-20-006248 |
Date: | 2020-09-30 |
Issuer: | AMARIN CORP PLC\UK (AMRN) |
Original Submission Date: |
THERO JOHN F
C/O AMARIN PHARMA, INC.
440 US HIGHWAY 22
BRIDGEWATER, NJ 08807
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
ORDINARY SHARES | 2020-09-30 | M | 6,737 | a | $0.00 | 2,536,196 | direct | ||
ORDINARY SHARES | 2020-09-30 | M | 6,737 | a | $0.00 | 2,542,933 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
RESTRICTED STOCK UNITS | 0.0 | 2020-09-30 | deemed execution date | M | 6,737 (d) | ordinary shares 6,737 | $0.00 | 74,096 | direct | |||
RESTRICTED STOCK UNITS | 0.0 | 2020-09-30 | deemed execution date | M | 6,737 (d) | ordinary shares 6,737 | $0.00 | 74,096 | direct |
ID | footnote |
---|---|
f1 | the ordinary shares may be represented by american depositary shares, each of which currently represents one ordinary share. |
f2 | as previously reported on february 27, 2020, on may 15, 2017, the reporting person was granted 970,000 restricted stock units ("rsus") under the amarin corporation plc stock incentive plan (the "plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on february 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. the tranches vest ratably over 36 months beginning september 30, 2018 subject to achievement of the performance criteria and continued employment of the reporting person as provided in the rsu award agreement between the issuer and reporting person. the twenty-fifth vesting event occurred on september 30, 2020. the performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. |
f3 | not applicable. |
f4 | please see the section titled "remarks" below for additional information. |
f5 | each rsu represents a contingent right to receive one ordinary share or cash in lieu thereof at the issuer's discretion. |